As of 2025-12-26, the Relative Valuation of Recursion Pharmaceuticals Inc (RXRX) is (23.19) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.40 USD, the upside of Recursion Pharmaceuticals Inc based on Relative Valuation is -627.1%.
The range of the Relative Valuation is (22.68) - (24.20) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.5x - 17.6x | 17.0x |
| Forward P/E multiples | 15.7x - 17.6x | 16.6x |
| Fair Price | (22.68) - (24.20) | (23.19) |
| Upside | -615.5% - -650.0% | -627.1% |
| Date | P/E |
| 2025-12-24 | -3.20 |
| 2025-12-23 | -3.17 |
| 2025-12-22 | -3.20 |
| 2025-12-19 | -3.09 |
| 2025-12-18 | -3.23 |
| 2025-12-17 | -3.40 |
| 2025-12-16 | -3.05 |
| 2025-12-15 | -3.05 |
| 2025-12-12 | -3.15 |
| 2025-12-11 | -3.33 |
| 2025-12-10 | -3.47 |
| 2025-12-09 | -3.47 |
| 2025-12-08 | -3.50 |
| 2025-12-05 | -3.42 |
| 2025-12-04 | -3.57 |
| 2025-12-03 | -3.39 |
| 2025-12-02 | -3.14 |
| 2025-12-01 | -3.17 |
| 2025-11-28 | -3.36 |
| 2025-11-26 | -3.20 |
| 2025-11-25 | -3.17 |
| 2025-11-24 | -3.15 |
| 2025-11-21 | -3.03 |
| 2025-11-20 | -2.80 |
| 2025-11-19 | -2.93 |
| 2025-11-18 | -3.02 |
| 2025-11-17 | -2.99 |
| 2025-11-14 | -3.01 |
| 2025-11-13 | -3.15 |
| 2025-11-12 | -3.38 |
| 2025-11-11 | -3.42 |
| 2025-11-10 | -3.28 |
| 2025-11-07 | -3.36 |
| 2025-11-06 | -3.36 |
| 2025-11-05 | -3.60 |
| 2025-11-04 | -3.63 |
| 2025-11-03 | -3.95 |
| 2025-10-31 | -4.01 |
| 2025-10-30 | -4.10 |
| 2025-10-29 | -4.26 |
| 2025-10-28 | -4.29 |
| 2025-10-27 | -4.58 |
| 2025-10-24 | -4.39 |
| 2025-10-23 | -4.16 |
| 2025-10-22 | -4.18 |
| 2025-10-21 | -4.44 |
| 2025-10-20 | -4.85 |
| 2025-10-17 | -4.26 |
| 2025-10-16 | -4.62 |
| 2025-10-15 | -4.93 |